DFC Advisory Services LLC, dba TW Research Group may from time to time in our articles, reports, and interviews offer our own opinions concerning our featured companies, or the business spaces and market segments in which they operate. Any opinions we may offer are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers and viewers, and therefore should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research and all investment decisions are solely the responsibility of the reader. We are NOT a registered broker/dealer/analyst/adviser. We hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Our publications cannot not be construed as a recommendation to buy or sell a security or to provide any investment advice.
Our publications do not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications. Trading securities involves extreme risk and requires professional guidance. TW Research Group does not give specific trading advice, and no representation or claim is made that our publications contain a thorough analysis of each security. You should discuss your asset allocation, and the risk tolerance level appropriate for your personal financial situation, with a professional licensed financial planner and adviser. TW Research Group LLC encourages readers and viewers to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: http://www.sec.gov prior to investing in anything. You should also not make any trades or decisions based upon anything said or written with regard to investments without consulting a professional financial planner/adviser. The content provided by TW Research Group is provided solely as an informational aid. Past performance is not indicative of future results. TW Research Group is not liable for any trading losses you may incur as a result of our publications, market updates, news alerts and corporate profiles. Our publications are NOT a solicitation or recommendation to buy, sell or hold securities.
This website is provided for informational purposes only and should not be construed as a solicitation or an offer to buy or sell any security or related financial instrument. The information, materials or opinions contained in this website are subject to change at any time by TW Research Group without prior notice and we are not obligated to update or keep current the information contained herein. You should consider the information on its own merits whether it is suitable for your personal needs, investment objectives, and specific circumstances. We recommend that you consult with a licensed, qualified professional before making any investment decisions.
Some of the securities mentioned on this website may not be registered in the jurisdiction in which you are located. We urge you to seek legal advice before offering or selling any unregistered security.
TW Research Group and its officers may have been compensated by or have an equity interest – restricted and/or unrestricted – in the companies referred to on this website. TW Research Group is currently engaged with Amryt Pharma, ParkerVision, Inc., TFF Pharmaceuticals, Fortress Biotech, INmune Bio, Anixa Biosciences, Lantern Pharma, LexaGene and Summit Wireless to assist with investor relations. ParkerVision has issued 200,000 warrants to TW Research Group. TFF Pharmaceuticals has issued 25,000 warrants to TW Research Group. Fortress Biotech previously paid TW Research Group $4,000 and has issued 100,000 warrants to TW Research Group. INmune Bio pays TW Research Group a monthly retainer of $2,000 and has issued 20,000 shares to TW Research Group. Anixa Biosciences pays TW Research Group a has issued 135,000 warrants to TW Research Group. Lantern Pharma pays TW Research Group a monthly retainer of $3,500. Amryt Pharma pays TW Research Group a monthly retainer of $4,000. LexaGene pays TW Research Group a monthly retainer of $2,500 and has issued 100,000 warrants to TW Research Group.
In addition, the following companies have previously compensated TW Research: Summit Wireless, Catasys Corp. (OnTrak), Dyadic Inc., BioVie, HyreCar, Hancock Jaffe, Patriot One, Bioasis, Monaker Group, FTE Networks and Muscle Maker Grill.